Étiquette : Compassionate use
-
Media Coverage: Advanced BioDesign Featured in Le Figaro: Accelerating Innovation Against Resistant Cancers
Advanced BioDesign is honored to be featured in Le Figaro Économie, which highlights our cutting-edge approach to overcoming cancer resistance through targeted inhibition of ALDH1—a key enzyme that enables tumor survival and relapse. Our lead compound, ABD-3001, currently in Phase 1 clinical trials for acute myeloid leukemia (AML), has shown promising biological activity even at…
-
Advanced BioDesign announces first patient treated under compassionate access for ABD-3001 in relapse and refractory T-cell cell acute lymphoblastic leukemia
Lyon (France), September 4th, 2025 – Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, today announced that the first patient in France has been treated with its lead investigational drug, ABD-3001, under a compassionate access authorization for relapsed and refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL). This treatment…
Advanced BioDesign 